Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST
Company Participants
Christopher Gibson – Co-Founder, CEO & Director
Najat Khan – Chief R&D Officer, Chief Commercial Officer and Director
Conference Call Participants
Yuchen Ding – Jefferies LLC, Research Division
Presentation
Yuchen Ding
Jefferies LLC, Research Division
Good morning. Welcome to the Jefferies London Healthcare Conference. My name is Dennis Ding, biotech analyst here at Jefferies. I have the wonderful pleasure of having Recursion Pharmaceuticals up here with us. We have Chris Gibson and also Najat Khan here with us. So thank you so much for coming.
Christopher Gibson
Co-Founder, CEO & Director
Thanks for having us.
Najat Khan
Chief R&D Officer, Chief Commercial Officer and Director
Thanks for having us.
Question-and-Answer Session
Yuchen Ding
Jefferies LLC, Research Division
So before we jump in, maybe just give some opening remarks in terms of some of the transition here, Najat. And just give us an update in terms of what’s going on in terms of like the CEO and what kind of new thinking that you would be providing the company as CEO? And any kind of priorities for you over the next 12 to 18 months?
Christopher Gibson
Co-Founder, CEO & Director
Go ahead.
Najat Khan
Chief R&D Officer, Chief Commercial Officer and Director
Yes. No, first of all, thanks for having us. Great to be here. Yes. I mean, I think from a transition perspective, like very, very excited that we get to continue to partner. Chris will be the Chair of the Board. I’ve been at Recursion for 18 months. So I really had an opportunity to get to know the company joined before we did the Exscientia special combination.
From a perspective of going forward, it’s going to be doubling down on 2, 3 areas that
